News

July 25, 2018

Indivumed Launches New Biospecimen Product Lines

Indivumed is known for providing high-quality, ischemia-controlled biospecimens from within our clinical network. In addition to these Premium Grade specimens, we now offer two new lines of formalin-fixed paraffin-embedded (FFPE) tissue biospecimens – Advanced Grade and Basic Grade.

Read More

July 25, 2018

Indivumed Officially Launches Premium Grade Longitudinal Cell-Free Plasma Biospecimens

Indivumed is known for providing high-quality, ischemia-controlled biospecimens from within our clinical network. To further support the fight against cancer, we now offer high-quality Premium Grade longitudinal cell-free plasma specimens from within our growing oncologist network.

Read More

March 27, 2018

Indivumed Receives Innovation Award at EIB Venture Debt Summit

Indivumed received the 2018 Innovation Award at the inaugural EIB Venture Debt Summit held in Luxembourg on March 22, 2018.

Read More

Press

July 03, 2018

Indivumed signs agreement with IMCB to build the first global, multiomics cancer database

Indivumed GmbH and A*STAR’s Institute of Molecular and Cell Biology (IMCB) in Singapore have signed an agreement to perform proteomic and phosphoproteomic analysis of thousands of tissue samples from Indivumed’s unique biobank.

Read More

January 16, 2018

The Salk Institute and Indivumed Partner to Advance Global Cancer Research

Salk and Indivumed have established a strategic partnership to advance research in precision oncology and personalized medicine by utilizing the highest quality molecular and clinical data in cancer

Read More

January 09, 2018

Investment Plan for Europe: EIB grants loan of EUR 40m to Indivumed

The European Investment Bank (EIB) will provide a loan of EUR 40m to Indivumed GmbH, a physician-led, integrated global oncology company providing high-content tumour data and an optimum quality biobank to third parties such as biopharmaceutical companies and research institutes.

Read More

September 19, 2017

Indivumed and Helomics partner to unlock the power of cancer biospecimens for drug discovery and development

Indivumed GmbH (Indivumed) and Helomics® Corporation (Helomics) announce their intentions to collaborate to analyze human cancer biospecimens and annotated clinical data from consenting patients around the world, enabling cutting-edge basic and translational research in cancer.

Read More

Product Information

Videos